Ensitrelvir or S-217622, a potent inhibitor of SARCov2 main protease from Japan shows activity against COVID19 Variants of concern in animals studies and is poised to enter clinical trials.
#COVID19 #Ensiltrevir #Japan #ProteaseInhibitor #S217622
science.org/doi/10.1126/sc…
Ensiltrevir blocks SARSCov2 Main protease after viral entry. #Ensiltrevir science.org/doi/10.1126/sc…
Prophylactic treatment of S-217622 controls viral burden and disease in hamsters inoculated with SARS-CoV-2
science.org/doi/10.1126/sc…
S-217622 retains antiviral activity against SARS-CoV-2 VOCs in vivo
science.org/doi/10.1126/sc…
Therapeutic treatment with S-217622 decreased the viral load of SARS-CoV-2 and reduces disease severity in hamsters.
Histopathological analysis of the lungs isolated from SARS-CoV-2-infected, antiviral-treated hamsters.
science.org/doi/10.1126/sc…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.